Evaluation of patient perspective of point of care testing and medication: Dispensing by community pharmacists for Streptococcus pyogenes and influenza

Abstract

BackgroundRecent state-level legislation allows pharmacies to implement protocols for the testing and treatment of influenza and group A streptococcal pharyngitis infections, which may improve access. ObjectivesThis study evaluated patient perspectives on testing and treatment of influenza or streptococcal pharyngitis infections in the pharmacy and evaluated patient acceptance, willingness to seek testing, and willingness to pay. MethodsThis study used a cross-sectional paper survey administered at the community pharmacy after receiving a coronavirus disease 2019 vaccine. The survey consisted of multiple choice and rank order. Surveys were anonymous and returned after completion before leaving the pharmacy. Survey data were entered into an Excel database for analysis. ResultsThere were a total of 152 respondents. Most of them were older than the age of 50 years and female. Most (89%) have a primary care provider (PCP) and their preferred location for testing was their PCP or a walk-in, quick care setting. More than half of the respondents stated that they would use the pharmacy as a source for testing and treatment for streptococcal pharyngitis infections and influenza. Half of the respondents pay an office copay visit of less than $15 and 29% pay $25-$50 per visit. The majority of respondents (62%) were willing to pay $25 or more out of pocket for testing. ConclusionAlthough the pharmacy was not the preferred site for testing, more than half of the respondents stated that they would use the pharmacy for testing and treatment. Most respondents’ willingness to pay was more than their copayments for office visits, suggesting some may value the convenience of testing and treatment at the pharmacy.